Conversely, downregulation of FBP1 and HPGD, coupled with their hypermethylation, reinforces the metabolic shift toward glycolysis and potentiates prostaglandin-driven inflammation, both of which are key drivers of tumor progression (Sun et al., 2021; Xu et al., 2022). The gene discussed is FBP1; the disease is neoplasm.